Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...

The federal government is no longer broadly recommending several vaccines as part of the Trump administration and Health ...

How $2,670 split across three durable high-yield stocks can generate $300 in annual dividends without risky payouts.

HHS’s move Monday to overhaul the childhood vaccine schedule without public input marks Health Secretary Robert F. Kennedy Jr ...

Drugmakers hike prices 350 drugs in January, including Pfizer's COVID-19 vaccine and hospital drugs, with a median increase of 4%.

AI and digital health devices should not be viewed as replacements for health care professionals, but as tools that can be ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

IBD is rising worldwide and is now a global disease. With the expanding armamentarium of medical therapies, including biologics and small molecules, there is a decline in hospitalisation rates and IBD ...

In 2025, federal health agencies dismantled precedents in vaccine guidance, fracturing state-federal alignment and fueling concerns about public health guidance. HHS Secretary Robert F. Kennedy Jr.

Peptide therapeutics have progressed from insulin discovery to GLP-1 class molecules, revolutionizing diabetes treatment and ...